As expected, this increase in activity is sensitive to NFkB inhibition by wtNBD peptides suggesting that inhibition of NFkB activation may be an effective therapeutic approach for colon cancers regardless of SMAD4 status. The gene discussed is SMAD4; the disease is malignant colon neoplasm.